Jean-francois F. Ramee
La Roche, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 10, 2022
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 28, 2022
Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA-approval descriptive study with a geriatric oncology focus.
Journal: The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
Published: November 10, 2020
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Journal: The Lancet. Oncology
Published: March 09, 2020
Performance comparison of modified ComBat for harmonization of radiomic features for multicenter studies.
Journal: Scientific reports
Published: January 28, 2020
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Journal: Journal of hepatology
Published: October 30, 2018
Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study.
Journal: Clinical colorectal cancer
Published: December 02, 2015
KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer
Journal: Bulletin du cancer
Published: November 30, 2015
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: June 04, 2015
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 28, 2015
Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (Observatoire dédié au Cancer Bretagne / Pays de la Loire).
Journal: Oncologie (Paris, France)
Published: October 17, 2013
Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas.
Journal: Journal of clinical pathology
Published: January 20, 2012
Last Updated: 09/26/2026